Chromocell Therapeutics(CHRO) - 2025 Q2 - Quarterly Results

Filing Information This section provides essential details regarding the registrant, the filing date, and the general context of this Form 8-K submission Registrant and Filing Details This section provides the basic identification details for Pelthos Therapeutics Inc. as the registrant, including its jurisdiction, address, and contact information, for this Form 8-K filing dated August 18, 2025 - Registrant: Pelthos Therapeutics Inc.[2] - Date of Report: August 18, 2025[2] Registrant Contact and Identification Details | Detail | Value | | :--- | :--- | | Jurisdiction of incorporation | Nevada | | Commission File Number | 001-41964 | | IRS Employer Identification No. | 86-3335449 | | Principal Executive Office | 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 | | Registrant's telephone number | (919) 908-2400 | Securities and Status This section outlines the company's registered securities and its status as an emerging growth company, as defined by SEC regulations Registered Securities Information | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :--- | :--- | :--- | | Common Stock, par value $0.0001 per share | PTHS | The NYSE American LLC | - Pelthos Therapeutics Inc. is an emerging growth company[4] - The registrant utilizes the extended transition period for complying with new or revised financial accounting standards[4] Reported Events This section details the specific events being reported, including financial results, Regulation FD disclosures, and accompanying exhibits Item 2.02. Results of Operations and Financial Condition Pelthos Therapeutics Inc. reported its financial results for legacy operations for the three and six months ended June 30, 2025, and provided an update on its therapeutic programs via a press release (Exhibit 99.1) issued on August 18, 2025. This information is furnished but not deemed 'filed' for certain legal purposes - On August 18, 2025, Pelthos Therapeutics Inc. issued a press release summarizing financial results for legacy operations for the three and six months ended June 30, 2025[5] - The press release also provided an update on the Company's therapeutic programs[5] - A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference[5] - The information in this Item 2.02 and Exhibit 99.1 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, limiting certain liabilities[6] Item 7.01. Regulation FD Disclosure This item formally incorporates the information disclosed under Item 2.02, including the press release (Exhibit 99.1), to satisfy Regulation FD requirements, ensuring fair and broad disclosure of material non-public information - Information disclosed in Item 2.02, including Exhibit 99.1, is incorporated into this Item 7.01 by reference[7] Item 9.01. Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, specifically identifying the press release dated August 18, 2025, as Exhibit 99.1 List of Exhibits | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release, dated August 18, 2025. | Signatures This section provides the formal authorization and signatory details for the submitted report Authorization and Signatory The report is duly signed on behalf of Pelthos Therapeutics Inc. by its Chief Financial Officer, Francis Knuettel II, confirming its authorization and submission on August 18, 2025 - The report was signed on behalf of Pelthos Therapeutics Inc. on August 18, 2025[11] - Signatory: Francis Knuettel II, Chief Financial Officer[11]